QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer

Prior treatment

• Previously treated with immune checkpoint inhibitors, including but not limited to other anti-PD-1, anti-PD-L1 antibodies, CTLA-4 antibodies, or any treatments targeting immune co-stimulatory factors (such as antibodies targeting ICOS, CD40, CD137, GITR, OX40, etc.) or other mechanisms of tumor immunotherapy;
• Received immunosuppressive drugs or systemic corticosteroids for immunosuppression within 2 weeks prior to the study medication (more than 10mg/day of prednisone or other equivalent drugs), with the exception of local, ophthalmic, intra-articular, intranasal, and inhaled corticosteroids;
• Received traditional Chinese medicine with antitumor effects or drugs with immunomodulatory effects (such as thymic peptides, interferons, interleukin-2) within 2 weeks prior to the study;
• Experienced severe infections within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia;
• Received live vaccines or attenuated vaccines within 4 weeks prior to the first trial dose, with the exception of inactivated seasonal influenza vaccines;
• Patients who have undergone allogeneic bone marrow transplantation or solid organ transplantation;
• Participants who have undergone major surgery (such as laparotomy, thoracotomy, organ resection, etc.) and severe trauma within 28 days prior to the first dose, with the exception of implantable infusion devices;
• Uncontrolled other comorbidities, symptoms, or medical history, including: ① Those with one of the following cardiovascular or cerebrovascular diseases or risk factors: myocardial infarction, unstable angina, pulmonary embolism, acute/persistent myocardial ischemia, cerebrovascular accident, transient ischemic attack, or other clinically significant/requiring medication intervention arterial venous thrombosis, embolism, or cerebral ischemic events; symptoms of congestive heart failure within 6 months (New York Heart Association (NYHA) class III or above); ② History of clinically significant bleeding symptoms or obvious bleeding features within 1 month prior to the first dose, such as gastrointestinal bleeding, peptic ulcer bleeding, or vasculitis; ③ Clinical manifestations of active hemoptysis, active diverticulitis, abdominal abscess, and gastrointestinal obstruction; ④ Those with uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; ⑤ History of liver or kidney abnormalities or surgery;
• Any condition deemed by the investigator to pose a risk when receiving the study medication, or that would interfere with the safety evaluation of the study medication or the interpretation of the study results.

Other illness

• Participants with active, known, or suspected autoimmune diseases, or a history of autoimmune diseases, except for the following conditions: vitiligo, alopecia, Graves' disease, psoriasis, or eczema that does not require systemic treatment within the last 2 years, asymptomatic hypothyroidism or requiring only a stable dose of hormone replacement therapy (due to autoimmune thyroiditis), type 1 diabetes requiring only a stable dose of insulin replacement therapy, asthma that has completely resolved in childhood and does not require intervention in adulthood, or diseases that do not relapse without external triggers;
• Known allergic reactions to any components and/or excipients of the investigational medication;
• Active systemic infections requiring systemic treatment;
• Untreated chronic hepatitis B patients, or hepatitis B virus (HBV) carriers with HBV DNA greater than 1000 IU/mL, or patients with active hepatitis C. Non-active HBsAg carriers, treated and stable hepatitis B patients (HBV DNA \< 1000 IU/mL), and cured hepatitis C patients are eligible. Subjects with positive HCV antibodies are only eligible if HCV RNA testing is negative;
• Known active pulmonary tuberculosis (TB), suspected active TB patients should undergo chest X-ray and sputum tests, combined with clinical symptoms and signs to rule out;
• Immunodeficiency or human immunodeficiency virus (HIV antibody positive);
• Participants with active inflammatory bowel disease or a history of such diseases (such as Crohn's disease, ulcerative colitis, or chronic diarrhea). Participants who cannot swallow or have malabsorption syndrome, uncontrolled nausea, vomiting, diarrhea, or other gastrointestinal diseases that severely affect drug intake and absorption;
• Known interstitial lung disease, symptomatic or likely to hinder the detection or treatment of immune-related pneumonia;
• History of primary malignant tumors within the last 5 years;
• History of gastrointestinal perforation, gastrointestinal fistula, or female genital fistula;

Age

• Pregnant or nursing women; women of childbearing age who refuse to accept contraceptive measures during neoadjuvant immunotherapy;

Other

• Simultaneously participating in other interventional clinical trials, participation in observational and non-interventional clinical trials is allowed;

• Clinically diagnosed with untreated cervical cancer at stages IB3, IIA2, and resectable IIIC1r (according to the FIGO standards of 2018; determined by two senior physicians or above through gynecological examination and imaging studies);
• At baseline, there is at least one measurable tumor lesion according to the RECIST 1.1 criteria, with the size of the lesion primarily determined by magnetic resonance imaging;
• Pathologically confirmed cervical cancer, including squamous cell carcinoma (all grades), common type adenocarcinoma (Silva classification types A or B, or differentiated grades G1 or G2), and adenosquamous carcinoma (differentiated grades G1 or G2);
• Patients must be aged between 18 and 70 years inclusive;
• ECOG performance status score of 0 or 1;
• Laboratory tests: White blood cell count (WBC) ≥ 3.5 × 10\^9/L, neutrophil count (NEU) ≥ 1.5 × 10\^9/L, platelet count (PLT) ≥ 100 × 10\^9/L, serum bilirubin ≤ 1.5 times the upper limit of normal, transaminases ≤ 1.5 times the upper limit of normal, blood urea nitrogen (BUN) and creatinine (Cr) within normal limits;
• Capable of follow-up and good compliance;
• Able to sign an informed consent form, including adherence to the requirements and restrictions listed in the informed consent and this protocol.